Ginkgo bioworks stocks.

Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.

Ginkgo bioworks stocks. Things To Know About Ginkgo bioworks stocks.

Nov 22, 2023 · According to the issued ratings of 5 analysts in the last year, the consensus rating for Ginkgo Bioworks stock is Hold based on the current 1 sell rating, 3 hold ratings and 1 buy rating for DNA. The average twelve-month price prediction for Ginkgo Bioworks is $3.19 with a high price target of $6.00 and a low price target of $1.25. Learn more ... Ginkgo Bioworks Holdings Inc (NYSE: DNA) has seen a rise in its stock price by 10.85 in relation to its previous close of 1.29. However, the company has experienced a -2.05% decline in its stock price over the last five trading sessions. The Motley Fool reported 2023-12-01 that These companies are just getting started along the path of revenue ...Nov 24, 2023 · Is Ginkgo Bioworks a stock worth buying? When the stock began trading in September 2021, its valuation was around $15 billion. Today, it has a market capitalization of just $3.2 billion. Ginkgo Bioworks reported Q2 revenue of $81 million, down 44% YoY, mainly due to a decline in Biosecurity revenue. Read more about DNA stock here.A high-level overview of Ginkgo Bioworks Holdings, Inc. (DNA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Aug 18, 2021 · While Ginkgo Bioworks is an exciting company, the pricing of the SPAC stock leaves a lot of room for things to go wrong between now and the company's long-term projections. 1. Ginkgo Bioworks. Ginkgo Bioworks ( DNA) saw its shares fall by 69% over the last 12 months, but that could be just the opening that value-hunting investors need to start a position. Unlike ...

Complete Ginkgo Bioworks Holdings Inc. stock information by Barron's. View real-time DNA stock price and news, along with industry-best analysis.

Principal Financial Group Inc. increased its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) by 38.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 122,835 shares of the company’s stock after acquiring an additional …Great news for investors – Ginkgo Bioworks Holdings is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is $1.78, which is above what the ...Get the latest Ginkgo Bioworks Holdings Inc (DNA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.At Ginkgo Bioworks, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.Synthetic biology company Ginkgo Bioworks Holdings (DNA-4.79%) is down roughly 80% from its highs posted late last year. But rapidly growing revenues and a hefty cash balance, combined with ...

Company profile page for Ginkgo Bioworks Inc including stock price, company news, press releases, executives, board members, and contact information

Dec 1, 2023 · 2. Ginkgo Bioworks. Ginkgo Bioworks has scaled up the process of engineering organisms that can be used in a variety of industries, from agriculture to pharmaceuticals. Through the company's ...

Feb 24, 2023 · Ginkgo Bioworks ( DNA -7.19%) is a biotech that's operating on multiple bleeding edges of innovation as it works to engineer and manufacture biological cells at scale. Between its highly automated ... You can see the complete list of today’s Zacks #1 Rank stocks here. Ginkgo Bioworks Holdings, Inc. Price and EPS Surprise. Ginkgo Bioworks Holdings, Inc. Price and EPS Surprise.By William White, InvestorPlace Writer Jul 19, 2023. Ginkgo Bioworks (DNA) stock is rising higher on Wednesday after the company won a four-year, $18 million contract from DARPA.Third quarter 2023 Total revenue of $55 million, down from $66 million in the comparable prior year period, a decrease of 17% primarily driven by the expected ramp down of K-12 testing in Ginkgo's ...8,194,680. Aug 04 05:01 PM. open in yahoo open in reuters | open in marketwatch open in google open in EDGAR. DNA - Ginkgo Bioworks Holdings Inc - Stock screener for investors and traders, financial visualizations.See the latest DNA Stock price for Ginkgo Bioworks Holdings Inc and NYSE: DNA stock rating, related news, valuation, dividends and more to help you make …Oct 18, 2023 · Ginkgo Bioworks (DNA-7.19%) sells something very original: the large-scale design and production of organisms. And thanks to its innovations, the company has increased revenue almost 800% over the ...

3.90. Nikko Asset Management Americas, Inc. 3.67. ARK Genomic Revolution ETF. 3.25. The latest Ginkgo Bioworks Holdings stock prices, stock quotes, news, and …Aug 18, 2021 · While Ginkgo Bioworks is an exciting company, the pricing of the SPAC stock leaves a lot of room for things to go wrong between now and the company's long-term projections. Ginkgo Bioworks' stock was trading at $1.69 at the start of the year. Since then, DNA shares have decreased by 15.4% and is now trading at $1.43. View the best …Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 86.67% and 16.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead ...Jan 3, 2022 · Ginkgo Bioworks has a fantastic reputation of committing money to R&D. As an investor, I would look past current share pricing and focus on the potential 12-month upside of the company's technology.

Ginkgo Bioworks Holdings Inc’s stock is NA in 2023, NA in the previous five trading days and down 24.46% in the past year. Currently, Ginkgo Bioworks Holdings Inc does not have a price-earnings ratio. Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a -272.3% net profit margin. Year-over-year quarterly sales ...1. Ginkgo Bioworks. Down by 67% from a year ago, Ginkgo Bioworks ( DNA -7.32%) is a biotech growth stock that has a solid chance of being a favorite pick during the next bull market. While it isn ...

Ginkgo Bioworks Holdings Inc Stock (DNA) Forecast. The Ginkgo Bioworks Holdings Inc ( DNA) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $3.8461, representing a +163.43% increase from the current price of $1.46. The highest analyst price target is $7.2822, and the lowest is $0.4100.Food ingredient company Vivici has partnered with Ginkgo Bioworks to develop a range of new alternative dairy proteins created through precision fermentation, …Why Ginkgo Bioworks isn't a Buffett stock today. Warren Buffett tends to invest in businesses that have highly consistent earnings, low-cost operations, and, above all, sustainable competitive ...You can buy and sell Ginkgo Bioworks (DNA) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details.Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($0.37) to ($0.30) per share. Ginkgo Bioworks has not formally confirmed its next …Ginkgo Bioworks (NYSE:DNA) Is among the more prominent stocks in the synthetic biology space. The company is located in Boston, Massachusetts, which is a leading hub in the biotechnology industry.Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA) shareholders that were waiting for something to happen have been dealt a blow with a 30% share price drop in …

Ginkgo is expecting Total revenue of $250 - $260 million in 2023. Ginkgo revised its expectations for Cell Engineering revenue to $145 - $150 million in 2023, inclusive of $4 million of downstream ...

A high-level overview of Ginkgo Bioworks Holdings, Inc. (DNA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Now's a great time to invest in biotechs that have AI as a tailwind. Ginkgo Bioworks uses AI to run bioengineering projects for other biotechs. Recursion Pharmaceuticals uses AI to find good leads ...Is Ginkgo Bioworks a stock worth buying? When the stock began trading in September 2021, its valuation was around $15 billion. Today, it has a market capitalization of just $3.2 billion.Which Ginkgo Bioworks insiders have been buying company stock? The following insider purchased DNA shares in the last 24 months: Shyam Sankar ($512,000.00). How much insider buying is happening at Ginkgo Bioworks?Shares of Ginkgo Bioworks (NYSE: DNA) have had a disastrous 2022, with the company losing over 65% of its market capitalization so far.The biotech company focuses on utilizing genetic engineering ...Right now, of course, Ginkgo is unprofitable, and the stock market has no appetite for risky high-growth names. So while there was a lot of excitement when Ginkgo shares hit the market, the stock ...Next-generation biotech Ginkgo Bioworks Holdings ( DNA -3.50%) was one of the star stocks in its sector this week. According to data compiled by S&P Global Market Intelligence, the company's share ...Ginkgo further revised its expectation for Total revenue from $425 – $440 million to $460 – $480 million in 2022. Ginkgo revised its expectation for Foundry revenue to $150 – $170 million in ...Dec 4, 2023 · The consensus among analysts is that Ginkgo Bioworks Holdings Inc (DNA) is a Hold stock at the moment, with a recommendation rating of 2.67. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 9 have rated it as a Hold, with 3 advising it as a Buy. 1 have rated the stock as Underweight.

BOSTON, Jan. 12, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today preliminary performance updates for the year ended December ...Ginkgo Bioworks Quote Info ; Trades, 17,938 ; 52 Week Range, 1.12 - 2.545 ; VWAP, $ 1.43 ; Dollar Volume, $ 11,728,554 ; Volume, 8,188,147.Ginkgo Bioworks announces $100 million equity offering. Read more to see why it has been a very strange couple of days for DNA stock. Ginkgo Bioworks announces $100 million equity offering. Read ...Instagram:https://instagram. composer trade reviewa g edwardsai stock software2024 recession You can see the complete list of today’s Zacks #1 Rank stocks here. Ginkgo Bioworks Holdings, Inc. Price and EPS Surprise. Ginkgo Bioworks Holdings, Inc. Price and EPS Surprise. nvidia optionsnfts to invest in Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($0.37) to ($0.30) per share. Ginkgo Bioworks has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More.Ginkgo Bioworks Holdings Inc. analyst ratings, historical stock prices, earnings estimates & actuals. DNA updated stock price target summary. best technology mutual fund Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food …Ginkgo Bioworks has a fantastic reputation of committing money to R&D. As an investor, I would look past current share pricing and focus on the potential 12-month upside of the company's technology.Barron's 400. Research & Ratings. U.S.: NYSE. About Ginkgo Bioworks Holdings Inc. Research & Ratings. Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes ...